BioTuesdays

Tag - Stifel

Disc-Medicine-Logo
Markets

Stifel starts Disc Medicine at buy; PT $37

Stifel launched coverage of Disc Medicine (NASDAQ:IRON) with a “buy” rating and $37 price target. The stock closed at $28.10, up $2.34, on April 20. “Our positive thesis is predicated on optimism for the company’s lead...

April 21, 2023
Theseus-Logo
Markets

Stifel starts Theseus Pharma at buy; PT $24

Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...

March 16, 2023
Mineralys-logo
Markets

Stifel starts Mineralys at buy; PT $45

Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...

March 7, 2023
Compass-Logo
Markets

Stifel starts Compass Therapeutics at buy; PT $9

Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...

January 27, 2023
Sight-Sciences-Logo
Markets

Stifel ups Sight Sciences to buy after survey

Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...

January 6, 2023
OmniAb Logo
Markets

Stifel starts OmniAb at buy; PT $12

Stifel launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and $12 price target. The stock closed at $2.61 on Nov. 25. Analyst Stephen Willey writes that OmniAb represents the construction of a high-throughput...

November 28, 2022